NorthWest Biotherapeutics Inc (NWBO)

[MI Dendream]

IDH analysis has nothing to do with the phase III data analysis. The comparison group does not have IDH mutation data to stratify by. It cannot be used in the DCVAX phase III determination aside from possibly playing a role in early vs late, but the uncertainty introduced there is hardly worth the effort and most would argue is counterproductive and should not be looked at for that reason as it was not block randomized upon.

This is important to FDA buying in to no more placebo as it is barbaric in GBM and how one answers the question of, how then do you propose we address this dilemma that you have created in the future?